Abstract

Scholar Rock Holding Corp will report fiscal first-quarter 2026 results on May 07, 2026 Pre-Market, and investors are watching EPS losses, operating burn, and collaboration revenue signals tied to the apitegromab and SRK-181 programs.

Market Forecast

Current-quarter forecasts suggest total revenue near 0.00 million US dollars, adjusted EPS at approximately -0.80 with a year-over-year improvement of 21.13%, and EBIT around -95.60 million US dollars with a year-over-year improvement of 39.85%; gross margin and net margin are not guided. The main business remains collaboration-related revenue with limited recognized amounts, and the development portfolio’s advancement is the principal driver of near-term catalysts rather than top-line growth. The most promising segment is the collaboration stream, currently at 0.38 million US dollars last quarter and poised for lumpy recognition depending on milestone timing, with uncertain year-over-year comparability.

Last Quarter Review

Scholar Rock Holding Corp posted last quarter revenue of 0.00 million US dollars, GAAP net loss attributable to the parent company of 90.97 million US dollars with quarter-on-quarter change of 11.01% improvement, while gross margin and net margin were not applicable and adjusted EPS was -0.88 with a year-over-year improvement of 44.26%. The quarter reflected ongoing R&D investment and operating discipline, with EBIT of -91.90 million US dollars improving versus the prior year. Main business highlights showed collaboration-related revenue of 0.38 million US dollars, with recognition dependent on contract progress and timing.

Current Quarter Outlook

Main operating drivers

The key operating drivers this quarter are expected to be R&D program momentum and cost control rather than recognized revenue. With revenue projected at 0.00 million US dollars, the P&L depends on operating expenses and the cadence of clinical execution. Management’s focus on advancing lead assets typically influences operating loss and cash runway, which investors will parse through the EBIT and EPS trajectory.

Operating loss is forecast to narrow year over year given the projected EBIT of -95.60 million US dollars and EPS of -0.80, implying continued progress on expense management or trial phasing. Any commentary on clinical trial enrollment, regulatory discussions, or milestone potential could inform whether operating losses continue to trend better than the prior year. Cash position and burn rate commentary will be crucial for assessing funding visibility through near-term catalysts.

Gross margin and net margin are not meaningful with immaterial revenue, so investors will instead evaluate qualitative updates. In this context, clarity on program prioritization and spend discipline can overshadow the lack of top-line growth. The company’s ability to align operating expenses with study timelines is a central factor to the quarterly loss profile.

Most promising revenue contributor

The collaboration line remains the only recognized revenue stream, recorded at 0.38 million US dollars last quarter. Forecasts imply minimal to zero revenue recognition this quarter, highlighting the inherently lumpy nature tied to contract milestones and service delivery under collaboration accounting. Year-over-year comparability is uncertain because recognition depends on timing, not ongoing product sales.

Investors will focus less on the absolute revenue print and more on whether any new or expanded collaborations could provide milestone inflows later in 2026. Signals around potential partnership activity can quickly alter the revenue trajectory and provide non-dilutive funding. Absent new deals, collaboration revenue is unlikely to change the investment case in the near term.

If the company discloses visibility into milestone triggers or contract deliverables, consensus may recalibrate revenue expectations for subsequent quarters. Such detail can also influence how investors model R&D reimbursement percentages and the timing of cash receipts relative to expense recognition.

Factors most likely to impact the stock

The stock is likely to react to updates on clinical timelines, including enrollment and data readout visibility for core programs, as these define the path to value-creating catalysts. Any indication of regulatory interaction success or design refinements could de-risk development and support sentiment. Conversely, signals of delays or higher-than-anticipated R&D spend could weigh on shares despite an improving loss profile.

Guidance on operating runway and capital planning will be closely monitored. With revenue minimal, the balance sheet strategy—potential milestones, potential business development, or capital market activity—shapes dilution risk perception. If operating expense trends continue to improve year over year as projections imply, the market may reward better capital efficiency, provided clinical execution remains on track.

Finally, commentary on manufacturing readiness, quality systems, and potential commercial groundwork may also influence expectations, especially if management frames a path to registrational milestones. In the absence of product revenue, these operational markers provide the framework for future value realization.

Analyst Opinions

Bullish opinions are in the majority relative to bearish views among institutions tracking the company in recent months. Analysts emphasizing the near-term setup point to the projected improvement in adjusted EPS and EBIT year over year, arguing that disciplined operating execution and a clear clinical roadmap could narrow losses and extend runway. These commentators also highlight the optionality from collaboration structures and potential milestone economics as supportive to non-dilutive funding scenarios.

Several well-followed brokerage analysts have underscored the importance of this quarter’s qualitative updates over the nominal revenue print, noting that the model is development-stage and thus more sensitive to expense cadence and clinical progress signals than to top-line volatility. The majority view expects management to reiterate focus on lead programs and to provide additional texture on timelines that can anchor the next phase of investor expectations. Should the company outline tangible steps toward value-driving readouts while maintaining expense control, bullish analysts believe shares could find support on the improving loss trajectory.

In their aggregated assessments, supporters frame the current quarter as a bridge toward upcoming catalysts, with risk balanced by operational discipline and the potential for opportunistic partnership activity. The consensus tilt reflects confidence that year-over-year improvement in per-share losses and operating results can continue, while acknowledging that execution on clinical milestones remains the ultimate determinant of equity performance.